EVO vs SNY
Evotec SE and Sanofi, side by side — 6 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | EVO | SNY |
|---|---|---|
| Revenue | €797.0M | €43.6B |
| Net income | €-196.1M | €7.8B |
| Gross margin | 14.4% | 77.2% |
| Net margin | −24.6% | 17.9% |
| Return on equity | −18.9% | 10.5% |
| Diluted EPS | −€1.11 | €6.37 |
| Dividend / share | — | €3.92 |
| Payout ratio | — | 61.1% |
| Free cash flow | €-99.2M | — |
| Equity | €952.5M | €71.4B |
| Net debt / equity | −0.02× | 0.15× |
| Current ratio | 1.98× | 1.09× |
| Revenue CAGR 5y | 12.3% | 3.9% |
| Profit CAGR 5y | — | −8.7% |
SNY bills 54.7× the revenue of EVO, and EVO closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
6 years side by side
| Fiscal year | EVO | SNY |
|---|---|---|
| FY2024 | €797.0M | €41.1B |
| FY2023 | €781.4M | €37.8B |
| FY2022 | €751.4M | €37.7B |
| FY2021 | €618.0M | €37.8B |
| FY2020 | €500.9M | €36.0B |
| FY2019 | €446.4M | €36.1B |
Net income by year
Bottom line
| Fiscal year | EVO | SNY |
|---|---|---|
| FY2024 | €-196.1M | €5.6B |
| FY2023 | €-83.9M | €5.4B |
| FY2022 | €-175.7M | €8.4B |
| FY2021 | €215.5M | €6.2B |
| FY2020 | €6.3M | €12.3B |
| FY2019 | €38.2M | €2.8B |
Advertisement
AdSense · Rectangle 336×280